Notwithstanding positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from pharmacy benefit managers. The companies are https://lexiekilh674029.mybuzzblog.com/22131547/copyright-s-medication-faces-is-dealing-with-pbm-challenges-the-look-at-reimbursement-fights